Biohaven Ltd. (NYSE:BHVN) Shares Sold by First Turn Management LLC

First Turn Management LLC decreased its stake in shares of Biohaven Ltd. (NYSE:BHVN) by 13.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 315,816 shares of the company’s stock after selling 50,203 shares during the period. Biohaven makes up 2.5% of First Turn Management LLC’s portfolio, making the stock its 17th biggest position. First Turn Management LLC owned about 0.33% of Biohaven worth $15,781,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of BHVN. Sei Investments Co. increased its stake in Biohaven by 25.4% during the 1st quarter. Sei Investments Co. now owns 18,440 shares of the company’s stock valued at $1,008,000 after buying an additional 3,730 shares during the period. ProShare Advisors LLC increased its stake in Biohaven by 8.5% during the 1st quarter. ProShare Advisors LLC now owns 12,291 shares of the company’s stock valued at $672,000 after buying an additional 967 shares during the period. Vanguard Group Inc. increased its stake in Biohaven by 280.5% during the 1st quarter. Vanguard Group Inc. now owns 6,308,853 shares of the company’s stock valued at $345,031,000 after buying an additional 4,650,702 shares during the period. Advisors Asset Management Inc. increased its stake in Biohaven by 93.4% during the 1st quarter. Advisors Asset Management Inc. now owns 14,273 shares of the company’s stock valued at $781,000 after buying an additional 6,893 shares during the period. Finally, Capital International Investors increased its stake in Biohaven by 0.3% during the 1st quarter. Capital International Investors now owns 671,414 shares of the company’s stock valued at $36,720,000 after buying an additional 2,063 shares during the period. Institutional investors and hedge funds own 88.78% of the company’s stock.

Insider Buying and Selling

In other Biohaven news, Director Gregory Bailey acquired 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 24th. The shares were purchased at an average price of $44.19 per share, with a total value of $220,950.00. Following the completion of the transaction, the director now owns 1,620,071 shares in the company, valued at $71,590,937.49. The trade was a 0.31 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director John W. Childs acquired 21,052 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average cost of $47.50 per share, for a total transaction of $999,970.00. Following the transaction, the director now owns 21,052 shares of the company’s stock, valued at approximately $999,970. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. 16.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Piper Sandler lifted their price objective on shares of Biohaven from $66.00 to $76.00 and gave the stock an “overweight” rating in a research note on Monday, September 23rd. Royal Bank of Canada lowered their price objective on shares of Biohaven from $68.00 to $66.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 13th. JPMorgan Chase & Co. lifted their price objective on shares of Biohaven from $55.00 to $68.00 and gave the stock an “overweight” rating in a research note on Thursday, October 3rd. Bank of America lifted their price objective on shares of Biohaven from $52.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Finally, William Blair raised shares of Biohaven to a “strong-buy” rating in a research note on Friday, August 30th. Thirteen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $63.42.

Biohaven Stock Performance

BHVN stock opened at $45.43 on Tuesday. The stock has a market cap of $4.59 billion, a P/E ratio of -4.86 and a beta of 1.31. The firm has a 50 day simple moving average of $48.34 and a 200 day simple moving average of $40.96. Biohaven Ltd. has a 52 week low of $26.80 and a 52 week high of $62.21.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.03). Sell-side analysts predict that Biohaven Ltd. will post -8.87 EPS for the current year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.